Colin Watts

Prof. Colin Watts


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
FMFlorent Mouliere
Florent Mouliere
DCDineika Chandrananda
Dineika Chandrananda
APAnna M. Piskorz
Anna M. Piskorz
EMElizabeth K. Moore
Elizabeth K. Moore
JMJames Morris
James Morris
NRNitzan Rosenfeld
Nitzan Rosenfeld
Selective sequencing or in silico analysis for differences in DNA fragment size can improve the detection of circulating tumor DNA.

3 June 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
AYAdam M H Young
Adam M H Young
NKNatsuhiko Kumasaka
Natsuhiko Kumasaka
FCFiona Calvert
Fiona Calvert
THTimothy R Hammond
Timothy R Hammond
AKAndrew Knights
Andrew Knights
DGDaniel J Gaffney
Daniel J Gaffney

10 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
RNRavi S. Narayan
Ravi S. Narayan
PMPiet Molenaar
Piet Molenaar
JTJian Teng
Jian Teng
FCFleur M. G. Cornelissen
Fleur M. G. Cornelissen
IRIrene Roelofs
Irene Roelofs
BWBart A. Westerman
Bart A. Westerman
Personalized cancer treatments using combinations of drugs with a synergistic effect is attractive but proves to be highly challenging. Here we present an approach to uncover the efficacy of drug combinations based on the analysis of mono-drug effects. For this we used dose-response data from pharmacogenomic encyclopedias and represent these as a drug atlas. The drug atlas represents the relations between drug effects and allows to identify independent processes for which the tumor might be particularly vulnerable when attacked by two drugs. Our approach enables the prediction of combination-therapy which can be linked to tumor-driving mutations. By using this strategy, we can uncover potential effective drug combinations on a pan-cancer scale. Predicted synergies are provided and have been validated in glioblastoma, breast cancer, melanoma and leukemia mouse-models, resulting in therapeutic synergy in 75% of the tested models. This indicates that we can accurately predict effective drug combinations with translational value.

Verified
Journal Article
Open access
PDF file
AFAlina Finch
Alina Finch
GSGeorgios Solomou
Georgios Solomou
VWVictoria Wykes
Victoria Wykes
UPUte Pohl
Ute Pohl
CBChiara Bardella
Chiara Bardella
CWColin Watts
Colin Watts
Diffuse gliomas are the most frequent brain tumours, representing 75% of all primary malignant brain tumours in adults. Because of their locally aggressive behaviour and the fact that they cannot be cured by current therapies, they represent one of the most devastating cancers. The present review summarises recent advances in our understanding of glioma development and progression by use of various in vitro and in vivo models, as well as more complex techniques including cultures of 3D organoids and organotypic slices. We discuss the progress that has been made in understanding glioma heterogeneity, alteration in gene expression and DNA methylation, as well as advances in various in silico models. Lastly current treatment options and future clinical trials, which aim to improve early diagnosis and disease monitoring, are also discussed.

19 November 2018 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
ISI. Spiteri
I. Spiteri
GCG. Caravagna
G. Caravagna
GCG.D. Cresswell
G.D. Cresswell
AVA. Vatsiou
A. Vatsiou
DND. Nichol
D. Nichol
ASA. Sottoriva
A. Sottoriva
Glioblastoma is the most common and aggressive adult brain malignancy against which conventional surgery and chemoradiation provide limited benefit. Even when a good treatment response is obtained, recurrence inevitably occurs either locally (∼80%) or distally (∼20%), driven by cancer clones that are often genomically distinct from those in the primary tumour. Glioblastoma cells display a characteristic infiltrative phenotype, invading the surrounding tissue and often spreading across the whole brain. Cancer cells responsible for relapse can reside in two compartments of residual disease that are left behind after treatment: the infiltrated normal brain parenchyma and the sub-ventricular zone. However, these two sources of residual disease in glioblastoma are understudied because of the difficulty in sampling these regions during surgery. Here, we present the results of whole-exome sequencing of 69 multi-region samples collected using fluorescence-guided resection from 11 patients, including the infiltrating tumour margin and the sub-ventricular zone for each patient, as well as matched blood. We used a phylogenomic approach to dissect the spatio-temporal evolution of each tumour and unveil the relation between residual disease and the main tumour mass. We also analysed two patients with paired primary-recurrence samples with matched residual disease. Our results suggest that infiltrative subclones can arise early during tumour growth in a subset of patients. After treatment, the infiltrative subclones may seed the growth of a recurrent tumour, thus representing the ‘missing link’ between the primary tumour and recurrent disease. These results are consistent with recognised clinical phenotypic behaviour and suggest that more specific therapeutic targeting of cells in the infiltrated brain parenchyma may improve patient’s outcome.

24 July 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
KSKirit Singh
Kirit Singh
KHKelly M. Hotchkiss
Kelly M. Hotchkiss
IPIan F. Parney
Ian F. Parney
JGJohn De Groot
John De Groot
SSSolmaz Sahebjam
Solmaz Sahebjam
MKMustafa Khasraw
Mustafa Khasraw